In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Insmed's current price exceeds the fair value by 4.2%, with high valuation variance across methods indicating uncertainty. Strong liquidity and growth contrast sharply with zero profitability and efficiency, reflecting a high-risk profile. Monte Carlo analysis shows minimal downside risk, suggesting limited near-term price decline potential.